
The FDA approved oral venglustat for neurological manifestations of type 3 Gaucher disease after the phase 3 LEAP2MONO trial showed superiority over imiglucerase on a combined ataxia and cognition measure.
What is the most common risk factor for Guillain-Barré Syndrome? Plus 4 other quick questions to test your knowledge.
Test your knowledge on vaccines and Guillain-Barré Syndrome with the 5 questions below.





